Moderna Inc. today announced an agreement with the U.S. government for the purchase of an additional 200 million doses of Moderna’s COVID-19 vaccine, along with an option to purchase other COVID-19 vaccine candidates in the biotech company’s development pipeline.

The purchase will bring the total number of federally owned doses to 500 million, with delivery stretching into 2022. Moderna said the additional doses could be used for primary vaccination, including children, for which Moderna has yet to receive Food and Drug Administration approval, or as a booster for those with waning antibody protection.

Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…